TSH Biopharm (ROCO:8432) ROCE %: 10.93% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:8432 TSH Biopharm Corp Ltd ROCO:8432
84 GF Score
Price NT$50.20
GF Value NT$78.92
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is TSH Biopharm ROCE %?

TSH Biopharm ROCO:8432 84 ROCE % is 10.93% as of Dec. 2025. GuruFocus rates ROCO:8432 with a GF Score™ of 84/100 and a GF Value™ of NT$78.92 (Significantly Undervalued). The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. TSH Biopharm's annualized ROCE % for the quarter that ended in Dec. 2025 was 10.93%.

TSH Biopharm  (ROCO:8432) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

TSH Biopharm ROCE % Related Terms

TSH Biopharm ROCE % Historical Data

* Premium members only.

The historical data trend for TSH Biopharm's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TSH Biopharm ROCE % Chart

TSH Biopharm Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.57 7.08 6.15 11.99 14.03

TSH Biopharm Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.45 11.05 12.63 22.37 10.93
ROCO:8432
84GF Score
TSH Biopharm Corp Ltd ROCO:8432
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TSH Biopharm ROCE % Calculation

TSH Biopharm's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=235.584/( ( (1842.193 - 208.895) + (1951.454 - 227.091) )/ 2 )
=235.584/( (1633.298+1724.363)/ 2 )
=235.584/1678.8305
=14.03 %

TSH Biopharm's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=187.584/( ( (2019.207 - 309.738) + (1951.454 - 227.091) )/ 2 )
=187.584/( ( 1709.469 + 1724.363 )/ 2 )
=187.584/1716.916
=10.93 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 10.93% mean?
TSH Biopharm (ROCO:8432) has a ROCE % of 10.93% as of Dec. 2025.
Is TSH Biopharm's ROCE % too high?
TSH Biopharm's current ROCE % is 10.93%. The Drug Manufacturers industry median ROCE % is 7.04. TSH Biopharm's value of 10.93% is 55.3% above this industry median. Overall, TSH Biopharm has a GF Score™ of 84/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TSH Biopharm's ROCE % compare to ZTS and UTHR?
TSH Biopharm's ROCE % of 10.93% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.04. TSH Biopharm's value of 10.93% is 55.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.04, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TSH Biopharm's current ROCE % of 10.93% is 55.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TSH Biopharm's current ROCE % is 10.93%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TSH Biopharm stock overvalued right now?
Based on GuruFocus' analysis, TSH Biopharm (ROCO:8432) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$78.92, compared to a current price of NT$50.20 — trading 36.4% below its estimated fair value. The current ROCE % is 10.93% and 55.3% above the Drug Manufacturers industry median of 7.04. TSH Biopharm's overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For TSH Biopharm (ROCO:8432), the current ROCE % is 10.93% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TSH Biopharm (ROCO:8432) Overvalued in 2026?

Based on GuruFocus' analysis, TSH Biopharm stock appears to be undervalued. The current stock price of NT$50.20 is trading 36.4% below its estimated GF Value™ of NT$78.92. GuruFocus considers TSH Biopharm to be Significantly Undervalued.

Key valuation signals for ROCO:8432:

  • ROCE %: 10.93%
  • GF Value™: NT$78.92 vs. price of NT$50.20 (36.4% below fair value)
  • GF Score™: 84/100 with 1 warning sign
  • Industry Position: 55.3% above the Drug Manufacturers median

No single metric tells the full story. See the ROCO:8432 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

TSH Biopharm Business Description

Address No.3-1, Park Street, 3rd Floor-1, Nangang District, Taipei, TWN, 115
TSH Biopharm Corp Ltd is engaged in sale of a variety of pharmaceuticals, chemical drugs and engaged in biotechnology services. The company specializes in the development, manufacture, and marketing of branded drugs for chronic diseases. Key therapeutic areas include cardiovascular, central nervous system, gastroenterology, and severe chronic diseases, alongside precision medicine/genetic testing services .The Company's revenue is earned domestically. It earns majority of its revenue from the sale of Lozenges.
84GF Score

Get the complete analysis for ROCO:8432

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$50.20
Price
NT$78.92
GF Value